NCT07213583View on ClinicalTrials.gov

Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Amyloid Transthyretin Cardiomyopathy
Interventions
DRUG

ALXN2220

Participants will receive ALXN2220 via IV infusion.

Trial Locations (6)

9713

RECRUITING

University Medical Center Groningen, Groningen

28222

RECRUITING

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda

31059

RECRUITING

CHU Toulouse - Hôpital Rangueil, Toulouse

35033

NOT_YET_RECRUITING

CHU de Rennes - Hôpital Pontchaillou, Rennes

69120

RECRUITING

Universitätsklinikum Heidelberg, Heidelberg

94000

NOT_YET_RECRUITING

Hôpital Henri Mondor, Créteil

Sponsors

Lead Sponsor

Neurimmune AG
All Listed Sponsors
collaborator

Alexion Pharmaceuticals, Inc.

INDUSTRY

lead

Neurimmune AG

INDUSTRY